Interstitial Lung Diseases – Case Studies & Multidisciplinary Discussions Master Class-ILD posttest

ILD posttest

Pdf Summary

The document contains post-test questions from an ILD (Interstitial Lung Disease) Master Class, aimed at assessing knowledge on various topics related to ILD. Here's a summary of the information provided:<br /><br />1. **Risk Factors for ILAs**: The document identifies various risk factors for the progression of Interstitial Lung Abnormalities (ILAs), including cigarette smoking, subpleural and nonfibrotic locations, and genetic factors like MUC5B polymorphism. It notably indicates that younger age is not a risk factor, as older age is more associated with progression.<br /><br />2. **RA-Associated ILD**: In the context of rheumatoid arthritis (RA), UIP is the most common pattern of ILD and carries the worst prognosis. The management might involve immunosuppression and antifibrotic therapies. Methotrexate is not recommended for treatment, and early screening is crucial as delayed detection worsens mortality outcomes.<br /><br />3. **Guidelines for Hypersensitivity Pneumonitis**: Differences between ATS and ACCP guidelines are highlighted, notably regarding diagnosis methodologies. Both categorize hypersensitivity pneumonitis into fibrotic and nonfibrotic forms but differ in the reliance on biopsy. ACCP allows a confident diagnosis based on CT scans coupled with known antigen exposure, whereas ATS/JRS/ALAT insists on biopsy confirmation.<br /><br />4. **Medications for PH-ILD**: The document mentions the exploration of treatments for pulmonary hypertension associated with ILD, noting that many trials have not been successful, including those for Sildenafil and Remodulin. However, Inhaled Treprostinil has shown benefits and is approved for this use.<br /><br />5. **Unclassifiable ILD**: Unclassifiable ILD is defined as inability to categorize ILD despite comprehensive assessments, not synonymous with idiopathic NSIP. It has a poor prognosis and tends to be progressive. Antifibrotics can help slow progression.<br /><br />The document references several studies and guidelines that support these insights, providing a comprehensive understanding of ILD risk factors, treatments, and classifications.

Keywords

Interstitial Lung Disease

ILD progression

Risk factors

RA-associated ILD

Hypersensitivity Pneumonitis

Pulmonary Hypertension

Unclassifiable ILD

Antifibrotic therapies

MUC5B polymorphism

Inhaled Treprostinil

Pulmonary Hypertension